Garuda Therapeutics

Edit info

Founded: 2021

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: RD/Clin0

Therapy area: Transfusion-dependent beta-thalassemia

Drug types: HEM, GEN, BON

Lead product: Undisclosed

Funding: $62M B Feb 2023; $72M A Sep 2021

Investors: Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, Aisling Capital, Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments

garudatx.com

linkedin.com

job board

Business:

Off-the-shelf hematopoietic stem cell therapies

Drug notes:

Undisclosed RD/Clin0 bone marrow failure

About:

Garuda Therapeutics is developing “off-the-shelf”, durable blood stem cell therapies to treat a range of diseases. Hematopoietic stem cells (HSCs) can be used to generate many different blood cell types from immune cells to red blood cells. HSCs also self renew. Currently, patients seeking a blood stem cell transplant must find a suitable donor which can place greater barriers for racial minority patients. As an alternative solution, Garuda is using their platform to generate “off-the-shelf” self-renewing HSCs to provide patients with rapid and broad access to consistent, durable and transgene-free stem cell therapies. Garuda’s blood cells have the potential to cure more than 70 diseases and eliminate the dependency on donor cells.